DAVID M. MOTT - 31 Dec 2021 Form 4 Insider Report for Epizyme, Inc.

Role
Director
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
31 Dec 2021
Net transactions value
+$23,750
Form type
4
Filing time
04 Jan 2022, 15:20:27 UTC
Previous filing
01 Oct 2021
Next filing
05 Jan 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $23,750 +9,500 +5.6% $2.50 178,685 31 Dec 2021 Direct F1
holding EPZM Common Stock, par value $0.0001 106,959 31 Dec 2021 See Note 2 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the fourth fiscal quarter of 2021. The shares were issued on the last day of the fourth fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter.
F2 The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the "Mott Trust"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest.